Efficacy and Safety Stress Urinary Incontinence Study

Urinary Incontinence, Stress Clinical Trial

Official title:

Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00475358
• Other study ID #: 6231
• Secondary ID: F1J-MC-SBBT
• Status: Completed
• Phase: Phase 3
• First received: May 16, 2007
• Last updated: May 16, 2007
• Start date: April 2003
• Est. completion date: February 2005

Study information

• Verified date: May 2007
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Study F1J-MC-SBBT will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: February 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Are greater than 20 years of age.

• Are female outpatients.

• Present with SUI based on the disease diagnostic criteria, average at least one incontinent episode per day on the screening diary, and have had symptoms of SUI for a minimum of 3 months prior to study entry.

• Are women of non-childbearing potential by reason of hysterectomy, other surgery, or natural menopause, or are women of childbearing potential who test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a medically accepted means of contraception (for example, intrauterine device [IUD], oral or injectable contraceptives, implant, barrier device, sterilization, abstinence, or sex with a vasectomized male partner) for the duration of the study. Women using oral contraceptives or hormone replacement therapy must have a stable dose and regimen for greater than or equal to 3 months prior to entry into the study.

• Have no language barrier, agree to comply with the requirements of the protocol, and sign a written informed consent document prior to entry into the study.

Exclusion Criteria:

• Suffer from severe constipation (for example, have impacted rectum at time of physical examination despite recent evacuation).

• Has a physical examination, neurological and/or vaginal examination results which, in the opinion of the investigator, should exclude the subject.

• Are on a medication regimen (including diuretics) for which dose and/or frequency has not been stable for at least 12 weeks prior to randomization, or is anticipated to change during the course of the study.

• Have had any major inpatient surgery within 3 months prior to study entry.

• Have current diagnosis of any of the following conditions, disorders, or diseases of the genito-urinary tract: Ureteric, bladder, urethral, or rectal fistula

• Uncorrected congenital abnormality leading to urinary incontinence

• Detrusor instability or noncompliant bladder

• Adult enuresis

• Voiding difficulty (i.e., subject complains of difficulty emptying their bladder).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Drug:
• Duloxetine

• Placebo

Locations

Country	Name	City	State
Taiwan	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Tao-Yuan

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess efficacy of duloxetine 80 mg/day for 8 weeks in women with stress urinary incontinence (SUI) compared with placebo as measured by percent change in incontinence episode frequency from baseline.
Secondary	To compare the efficacy of duloxetine with that of placebo as measured by the change in the disease-specific quality of life instrument (I QOL) scores from baseline to endpoint.
Secondary	To compare the efficacy of duloxetine with that of placebo in subject perceived improvement in SUI as measured by the Patient’s Global Impressions of Improvement (PGI I) questionnaire.
Secondary	To compare the safety of duloxetine with that of placebo in the treatment of SUI based on vital signs, laboratory values, and the occurrence of treatment-emergent adverse events (TEAEs).

External Links

•   Lilly Clinical Trial Registry